Better prediction for effectiveness of paroxetine

April 13, 2017, Max Planck Society

A third of patients with depression do not respond to the first antidepressant medication prescribed. Currently, the only approach available is one of trial and error. In this study, Max Planck scientists have identified a biosignature able to distinguish patients who will and will not respond to treatment with the antidepressant paroxetine. This study is an important step forward in personalised medicine.

The therapeutic response to antidepressants varies considerably between with depression. About one third of the patients do not respond to the first prescribed antidepressant, an outcome only known after four to six weeks of continuous medication. It is not uncommon for these patients to have to undergo several rounds of with different antidepressants in order to find a suitable and dose. Aside from the associated costs, this situation results in lengthy suffering and an elevated risk of suicide for the patient.

Biosignatures able to predict the antidepressant treatment outcome for each patient would provide a precise medical approach to replace the current trial and error medication regimen. Biosignatures are objective biological measurements that are already used in other areas of medicine, but are absent in psychiatry. Such biosignatures would be of great value, allowing the treating psychiatrist to predict whether a patient will respond favourably to an antidepressant drug at the outset or during the early course of treatment.

Pathways in the neurons of the hippocampus as biosignature

Scientists around Chris Turck at the Max Planck Institute of Psychiatry in Munich, in collaboration with Marianne Müller at the University of Mainz, have used mice to delineate relevant molecular pathways characteristic for the response or non-response to the antidepressant paroxetine. In this study, the scientists profiled proteins and metabolites present in the hippocampus. They found that glutamate and ubiquitin-proteasome pathways are associated with the response to antidepressants. Glutamate is one of the major neurotransmitters and plays a central role in various brain functions. Ubiquitination is a quality control process critical for the removal of damaged proteins.

The suitable drug from the beginning

The scientists then looked to see if these pathways could be used to identify which patients would and would not respond to treatment. They took blood samples from patients with Major Depressive Disorder and found that the biosignature profiles were capable of stratifying the clinical antidepressant response. Importantly, they were able to distinguish antidepressant responder and non-responder patients prior to starting medication. "Predictive biosignatures for the antidepressant treatment response will reduce lengthy treatment ordeals for the patient because we will know the most suitable from the get go. This is a great step forward in the personalised medicine approach in psychiatry" concludes Dongik Park, the paper's first author. According to Chris Turck, "Biosignatures will also help in drug development by providing new target information. Additionally, they will be useful for clinical trials of novel antidepressants for patients suffering from treatment resistant depression."

Explore further: Brain scan before antidepressant therapy may predict response

More information: D I Park et al. Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems, Translational Psychiatry (2017). DOI: 10.1038/tp.2017.39

Related Stories

Brain scan before antidepressant therapy may predict response

January 24, 2017
A functional MRI brain scan may help predict which patients will respond positively to antidepressant therapy, according to a new study published in the journal Brain.

Blood test to personalize depression treatment for the first time

June 6, 2016
Scientists at King's College London have developed a blood test that accurately and reliably predicts whether depressed patients will respond to common antidepressants, which could herald a new era of personalised treatment ...

Antidepressants induce resilience and reverse susceptibility

February 2, 2017
When they work, antidepressant medications may take weeks or months to alleviate symptoms of depression. Progress in developing new and more effective antidepressant treatments has been limited, though a new study published ...

Arthritis drug boosts effectiveness of antidepressant medication, study finds

November 11, 2016
Giving severely depressed patients the arthritis drug celecoxib (Celebrex) dramatically boosted the effectiveness of their antidepressant medication, a Loyola study has found.

Antidepressant efficacy varies for depressive symptom clusters

February 28, 2017
(HealthDay)—Antidepressant treatment efficacy varies for empirically-defined clusters of symptoms, according to a study published online Feb. 22 in JAMA Psychiatry.

Biomarkers for antidepressant treatment response

September 20, 2012
(Medical Xpress)—Researchers from King's College London's Institute of Psychiatry (IoP) have identified new biomarkers for antidepressant treatment response, an important step towards developing personalised treatments ...

Recommended for you

People with prosthetic arms less affected by common illusion

January 22, 2018
People with prosthetic arms or hands do not experience the "size-weight illusion" as strongly as other people, new research shows.

Study of learning and memory problems in OCD helps young people unlock potential at school

January 22, 2018
Adolescents with obsessive-compulsive disorder (OCD) have widespread learning and memory problems, according to research published today. The findings have already been used to assist adolescents with OCD obtain the help ...

Intensive behavior therapy no better than conventional support in treating teenagers with antisocial behavior

January 19, 2018
Research led by UCL has found that intensive and costly multisystemic therapy is no better than conventional therapy in treating teenagers with moderate to severe antisocial behaviour.

Babies' babbling betters brains, language

January 18, 2018
Babies are adept at getting what they need - including an education. New research shows that babies organize mothers' verbal responses, which promotes more effective language instruction, and infant babbling is the key.

College branding makes beer more salient to underage students

January 18, 2018
In recent years, major beer companies have tried to capitalize on the salience of students' university affiliations, unveiling marketing campaigns and products—such as "fan cans," store displays, and billboard ads—that ...

Inherited IQ can increase in early childhood

January 18, 2018
When it comes to intelligence, environment and education matter – more than we think.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.